Please Wait
Applying Filters...
Menu
$ API Ref.Price (USD/KG) : 86,022Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 7Fiasp

02 6NovoMix

03 1NovoMix/NovoLog Mix

04 6NovoRapid

05 1NovoRapid/NovoLog

06 2Novomix/Novolog Mix

07 2Novorapid/Novolog

08 11Ryzodeg

09 8Tresiba

10 5Xultophy

PharmaCompass

01

Brand Name : Tresiba

Insulin Degludec, Insulin Aspart

arrow
The MedTech Conference
Not Confirmed

Brand Name : Tresiba

arrow
The MedTech Conference
Not Confirmed

Insulin Degludec, Insulin Aspart

Main Therapeutic Indication : Diabetes

Currency : USD

2020 Revenue in Millions : 1,459

2019 Revenue in Millions : 1,506

Growth (%) : -3

blank

02

Brand Name : Ryzodeg

Insulin Degludec, Insulin Aspart

arrow
The MedTech Conference
Not Confirmed

03

Brand Name : NovoMix

Biphasic Insulin Aspart

arrow
The MedTech Conference
Not Confirmed

Brand Name : NovoMix

arrow
The MedTech Conference
Not Confirmed

Biphasic Insulin Aspart

Main Therapeutic Indication : Diabetes

Currency : USD

2020 Revenue in Millions : 1,567

2019 Revenue in Millions : 1,559

Growth (%) : 1

blank

04

Brand Name : NovoRapid

Insulin Aspart

arrow
The MedTech Conference
Not Confirmed

Brand Name : NovoRapid

arrow
The MedTech Conference
Not Confirmed

Insulin Aspart

Main Therapeutic Indication : Diabetes

Currency : USD

2020 Revenue in Millions : 2,753

2019 Revenue in Millions : 2,937

Growth (%) : -6

blank

05

Brand Name : Xultophy

Insulin Degludec, Insulin Aspart

arrow
The MedTech Conference
Not Confirmed

Brand Name : Xultophy

arrow
The MedTech Conference
Not Confirmed

Insulin Degludec, Insulin Aspart

Main Therapeutic Indication : Diabetes

Currency : USD

2020 Revenue in Millions : 398

2019 Revenue in Millions : 359

Growth (%) : 11

blank

06

Brand Name : Ryzodeg

Insulin Aspart

arrow
The MedTech Conference
Not Confirmed

Brand Name : Ryzodeg

arrow
The MedTech Conference
Not Confirmed

Insulin Aspart

Main Therapeutic Indication : Diabetes

Currency : USD

2020 Revenue in Millions : 210

2019 Revenue in Millions : 162

Growth (%) : 30

blank

07

Brand Name : Fiasp

Insulin Aspart

arrow
The MedTech Conference
Not Confirmed

Brand Name : Fiasp

arrow
The MedTech Conference
Not Confirmed

Insulin Aspart

Main Therapeutic Indication : Diabetes

Currency : USD

2020 Revenue in Millions : 225

2019 Revenue in Millions : 202

Growth (%) : 11

blank

08

Brand Name : Ryzodeg

Insulin Degludec, Insulin Aspart

arrow
The MedTech Conference
Not Confirmed

09

Brand Name : Fiasp

Insulin Aspart

arrow
The MedTech Conference
Not Confirmed

Brand Name : Fiasp

arrow
The MedTech Conference
Not Confirmed

Insulin Aspart

Main Therapeutic Indication : Diabetes

Currency : USD

2021 Revenue in Millions : 266

2020 Revenue in Millions : 222

Growth (%) : 26

blank

10

Brand Name : Xultophy

Insulin Degludec, Insulin Aspart

arrow
The MedTech Conference
Not Confirmed